Luye Pharma Group Ltd.: Depressive Disorder, Major trials
The registry lists 10 Depressive Disorder, Major studies with Luye Pharma Group Ltd. as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 8Phase 3 1Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese SubjectsEnrolling by invitationNCT07371065Phase 1
- To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release TabletsNot yet recruitingNCT06426485Phase 4
- A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)CompletedNCT04853407Phase 3
- A Relative Bioavailability Food Effect Study of LY03005CompletedNCT03822065Phase 1
- Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)CompletedNCT03785652Phase 1
- A Study of LY03005 vs PristiqCompletedNCT03733574Phase 1
- Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®CompletedNCT03357796Phase 1
- Pilot BA Study of New LY03005 vs PristiqCompletedNCT02988024Phase 1
- Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005CompletedNCT02271412Phase 1
- Safety, Tolerability and Pharmacokinetics Study of LY03005CompletedNCT02055300Phase 1